00:43 , Jan 13, 2018 |  BioCentury  |  Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market...
01:41 , May 5, 2017 |  BC Week In Review  |  Clinical News

Safety committee recommends continuation of Atossa's Ph I endoxifen trial

Atossa Genetics Inc. (NASDAQ:ATOS) said an independent safety committee recommended continuation to the next dosing level in a Phase I trial of breast cancer candidate endoxifen. The recommendation comes after the committee reviewed data from...
23:20 , Apr 7, 2017 |  BioCentury  |  Finance

Taking notice

  Political overhang during the first quarter kept generalists on the sidelines but provided a buying opportunity for life sciences specialists that led the sector to outperform. With “repeal and replace” in the rearview for...
19:31 , Mar 31, 2017 |  BC Week In Review  |  Financial News

Atossa Genetics completes follow-on

Drug delivery and cancer company Atossa Genetics Inc. (NASDAQ:ATOS) raised $4 million through the sale of 664,000 class A units at $0.75 and 3,502 class B units at $1,000 in a follow-on underwritten by Aegis...
19:56 , Feb 17, 2017 |  BC Week In Review  |  Financial News

Atossa proposes follow-on

On Feb. 13, drug delivery and cancer company Atossa Genetics Inc. (NASDAQ:ATOS) proposed to raise up to $4 million in a follow-on underwritten by Aegis Capital. Atossa Genetics Inc. (NASDAQ:ATOS), Seattle, Wash. ...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Reasonable rally

Steve Edelson, Senior Editor   It looks like biotech's rebound will continue through the end of the year, but not with enough gusto to match the third quarter, or to make up for losses in...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Financial News

Atossa Genetics completes follow-on

Atossa Genetics Inc. (NASDAQ:ATOS), Seattle, Wash.   Business: Cancer   Date completed: 2016-08-31   Type: Follow-on   Raised: $2.9 million   Shares: 1.2 million   Price: $2.50   Shares after offering: 3.8 million   Underwriter:...
07:00 , May 30, 2016 |  BC Week In Review  |  Financial News

Atossa Genetics financial update

Atossa Genetics Inc. (NASDAQ:ATOS), Seattle, Wash.   Business: Cancer   Date announced: 2016-05-27   Note: Atossa entered into a 30-month stock purchase agreement with Aspire Capital for up to $10 million.  ...
07:00 , Mar 14, 2016 |  BC Week In Review  |  Clinical News

Intraductal fulvestrant: Phase II started

Atossa began the open-label, U.S. Phase II 007 trial to compare intraductal fulvestrant delivered via its microcatheter device vs. intramuscular Faslodex fulvestrant in about 30 patients who are scheduled to undergo a mastectomy. Faslodex is...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Company News

Besins Healthcare, Atossa Genetics deal

Besins granted Atossa exclusive, worldwide rights to develop and commercialize afimoxifene gel to treat and prevent hyperplasia of the breast. Besins is eligible to receive 8-9% royalties for 15 years after commercialization. Atossa also received...